CLSA’s Brett Johnson provides analysis to The Mercury News on Senate Bill 17, legislation pending in Sacramento that will harm patient access to care and biotechnology innovation in California.
“Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients.” – William J. Newell, CEO, Sutro Biopharma & Vice Chairman, California Life Sciences Association.
CLSA connects and strengthens the entire life sciences community across our great state.
CLSA’s Brett Johnson provides analysis to the LA Times on priority legislation in Sacramento for the life sciences sector.
CLSA’s Brett Johnson provides analysis to the San Francisco Business Times on three major bills (SB 790, SB 17 and AB 215) the life sciences sector is facing in Sacramento.
Did you miss it? CLSA is happy to share an overview of what we saw, who we talked to, and what we can expect leading up to BIO 2018 in Boston next June.
CLSA featured in The Los Angeles Times, reacting to the President’s 2018 Budget Request, and what it would mean for the life sciences industry.
CLSA was recently featured in BOSS Magazine regarding our efforts to drive solution-oriented public policies and advocacy activities that sustain and support life sciences research, investment and innovation in California. View the executive profile for more.
CLSA President & CEO Sara Radcliffe reacts to the President’s proposed $6 billion cut to the NIH’s budget in this San Diego Union-Tribune article.
CLSA’s Brett Johnson, Sr. Director of Policy & Regulatory Affairs, provides analysis and cites concerns regarding Assembly Bill 265, legislations introduced in the California state legislature that would ban drug companies from offering consumers coupons for drugs that have a lower cost alternative.